Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.
作者信息
Doan Thuy, Arzika Ahmed M, Hinterwirth Armin, Maliki Ramatou, Zhong Lina, Cummings Susie, Sarkar Samarpita, Chen Cindi, Porco Travis C, Keenan Jeremy D, Lietman Thomas M
机构信息
Francis I. Proctor Foundation, San Francisco, CA
Carter Center, Niamey, Niger.
出版信息
N Engl J Med. 2019 Jun 6;380(23):2271-2273. doi: 10.1056/NEJMc1901535.
Abstract
摘要
相似文献
1
Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.
N Engl J Med. 2019 Jun 6;380(23):2271-2273. doi: 10.1056/NEJMc1901535.
2
Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).
PLoS Med. 2024 May 6;21(5):e1004386. doi: 10.1371/journal.pmed.1004386. eCollection 2024 May.
3
Macrolide and ketolide resistance with Streptococcus pneumoniae.
Med Clin North Am. 2006 Nov;90(6):1109-24. doi: 10.1016/j.mcna.2006.07.010.
4
Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial.
PLoS Med. 2010 Dec 14;7(12):e1000377. doi: 10.1371/journal.pmed.1000377.
5
Temporal Trends in Phenotypic Macrolide and Nonmacrolide Resistance for Streptococcus pneumoniae Nasopharyngeal Samples Up to 36 Months after Mass Azithromycin Administration in a Cluster-Randomized Trial in Niger.
Am J Trop Med Hyg. 2023 Oct 2;109(5):1107-1112. doi: 10.4269/ajtmh.23-0431. Print 2023 Nov 1.
6
A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae.
Int J Antimicrob Agents. 2004 Aug;24(2):95-104. doi: 10.1016/j.ijantimicag.2004.03.008.
7
Macrolide Resistance in .
Front Cell Infect Microbiol. 2016 Sep 21;6:98. doi: 10.3389/fcimb.2016.00098. eCollection 2016.
8
Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2006 Nov;50(11):3646-50. doi: 10.1128/AAC.00234-06. Epub 2006 Aug 28.
9
Macrolide resistance among invasive Streptococcus pneumoniae in Slovenia.
J Antimicrob Chemother. 2008 Sep;62(3):628-9. doi: 10.1093/jac/dkn202. Epub 2008 May 12.
10
Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2003 Sep;47(9):2765-9. doi: 10.1128/AAC.47.9.2765-2769.2003.
引用本文的文献
1
Geographic spillover of antimicrobial resistance from mass distribution of azithromycin.
medRxiv. 2025 Jul 23:2025.07.22.25331994. doi: 10.1101/2025.07.22.25331994.
2
Spillover of Azithromycin Mass Drug Administration and Child Survival: A Secondary Analysis of a Cluster-Randomized Clinical Trial.
JAMA Netw Open. 2025 Jul 1;8(7):e2519693. doi: 10.1001/jamanetworkopen.2025.19693.
3
Empiric Azithromycin in COVID-19 Impacts the Respiratory Microbiome and Antimicrobial Resistome without Anti-inflammatory Benefit.
Res Sq. 2025 Jun 20:rs.3.rs-6875205. doi: 10.21203/rs.3.rs-6875205/v1.
4
Azithromycin mass drug administration to reduce child mortality in Niger (AVENIR II): a master protocol for a cluster-randomized adaptive platform trial to evaluate community-based health interventions.
medRxiv. 2025 Jun 18:2025.06.17.25329431. doi: 10.1101/2025.06.17.25329431.
5
An adaptive multiarm randomised trial of biomedical and psychosocial interventions to improve convalescence following severe acute malnutrition in sub-Saharan Africa: Co-SAM trial protocol.
BMJ Open. 2025 May 24;15(5):e093758. doi: 10.1136/bmjopen-2024-093758.
6
Costs, Coverage, and Acceptability of Azithromycin Mass Administration to Children 1-11 Versus 1-59 Months Old to Reduce Mortality: A Cluster-Randomized Trial in Niger.
Am J Trop Med Hyg. 2025 Apr 8;112(6):1355-1363. doi: 10.4269/ajtmh.24-0723. Print 2025 Jun 4.
7
Mass distribution of azithromycin and child mortality among underweight infants in rural Niger: a subgroup analysis of the AVENIR cluster-randomised trial.
BMJ Open. 2025 Mar 27;15(3):e097916. doi: 10.1136/bmjopen-2024-097916.
8
Effect of biannual azithromycin on respiratory pathogens among symptomatic children: results from the randomised Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) I trial.
BMJ Glob Health. 2025 Feb 10;10(2):e016043. doi: 10.1136/bmjgh-2024-016043.
9
Minimal Impact on the Resistome of Children in Botswana After Azithromycin Treatment for Acute Severe Diarrheal Disease.
J Infect Dis. 2024 Jul 25;230(1):239-249. doi: 10.1093/infdis/jiae049.
10
Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 months into a trachoma mass drug administration campaign to reduce child mortality in Côte d'Ivoire.
PLOS Glob Public Health. 2024 Jul 10;4(7):e0003426. doi: 10.1371/journal.pgph.0003426. eCollection 2024.
本文引用的文献
1
Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review.
Lancet Infect Dis. 2019 Jan;19(1):e14-e25. doi: 10.1016/S1473-3099(18)30444-4. Epub 2018 Oct 3.
2
Mass Azithromycin Distribution and Community Microbiome: A Cluster-Randomized Trial.
Open Forum Infect Dis. 2018 Jul 24;5(8):ofy182. doi: 10.1093/ofid/ofy182. eCollection 2018 Aug.
3
Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.
N Engl J Med. 2018 Apr 26;378(17):1583-1592. doi: 10.1056/NEJMoa1715474.
4
MEGARes: an antimicrobial resistance database for high throughput sequencing.
Nucleic Acids Res. 2017 Jan 4;45(D1):D574-D580. doi: 10.1093/nar/gkw1009. Epub 2016 Nov 28.
Zotero 插件